$911 Million is the total value of Bain Capital Life Sciences Investors, LLC's 25 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 11.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVALENT INC | $204,614,675 | +1.0% | 2,697,267 | 0.0% | 22.46% | +38.0% | ||
| NEWAMSTERDAM PHARMA COMPANYordinary shares | $201,203,869 | -18.8% | 10,473,913 | 0.0% | 22.09% | +11.0% | ||
| Buy | DISC MEDICINE INC | $80,933,776 | -1.3% | 1,795,735 | +36.3% | 8.89% | +34.8% | |
| Buy | DIANTHUS THERAPEUTICS INC | $77,987,387 | -13.1% | 3,013,423 | +0.7% | 8.56% | +18.7% | |
| PHVS | PHARVARIS N V | $62,103,563 | -18.6% | 3,303,381 | 0.0% | 6.82% | +11.1% | |
| SVRA | SAVARA INC | $58,698,792 | -19.1% | 14,565,457 | 0.0% | 6.44% | +10.5% | |
| ANNX | Sell | ANNEXON INC | $41,401,119 | -33.7% | 8,449,208 | -2.9% | 4.54% | -9.4% |
| Buy | KYVERNA THERAPEUTICS INC | $25,262,775 | -67.9% | 3,368,370 | +6.5% | 2.77% | -56.1% | |
| TANGO THERAPEUTICS INC | $24,819,049 | +8.1% | 2,892,663 | 0.0% | 2.72% | +47.6% | ||
| SOLID BIOSCIENCES INC | $22,876,080 | -57.4% | 4,034,582 | 0.0% | 2.51% | -41.8% | ||
| MRSN | MERSANA THERAPEUTICS INC | $17,413,983 | -55.1% | 8,663,673 | 0.0% | 1.91% | -38.7% | |
| SYROS PHARMACEUTICALS INC | $14,189,009 | -3.6% | 2,749,808 | 0.0% | 1.56% | +31.8% | ||
| IPSC | New | CENTURY THERAPEUTICS INC | $13,796,421 | – | 5,410,361 | +100.0% | 1.52% | – |
| CABA | Buy | CABALETTA BIO INC | $12,341,731 | -55.3% | 1,649,964 | +2.0% | 1.36% | -38.9% |
| XFOR | X4 PHARMACEUTICALS INC | $9,811,155 | -58.3% | 16,915,784 | 0.0% | 1.08% | -43.0% | |
| ARQT | Sell | ARCUTIS BIOTHERAPEUTICS INC | $9,585,538 | -51.9% | 1,030,703 | -48.8% | 1.05% | -34.3% |
| AVIR | ATEA PHARMACEUTICALS INC | $8,227,462 | -18.1% | 2,485,638 | 0.0% | 0.90% | +11.9% | |
| RAPID MICRO BIOSYSTEMS INC | $5,566,810 | -32.0% | 8,434,560 | 0.0% | 0.61% | -7.1% | ||
| CCCC | Sell | C4 THERAPEUTICS INC | $5,137,024 | -45.0% | 1,111,910 | -2.7% | 0.56% | -24.8% |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $4,680,000 | -20.4% | 2,000,000 | 0.0% | 0.51% | +8.7% | |
| Buy | XILIO THERAPEUTICS INC | $3,586,714 | +18.4% | 3,785,450 | +34.9% | 0.39% | +61.5% | |
| Buy | MARINUS PHARMACEUTICALS INC | $2,653,186 | -78.9% | 2,267,680 | +62.7% | 0.29% | -71.2% | |
| INVIVYD INC | $1,979,555 | -75.2% | 1,799,595 | 0.0% | 0.22% | -66.2% | ||
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $1,100,000 | -70.4% | 1,000,000 | -66.7% | 0.12% | -59.5% |
| NEWAMSTERDAM PHARMA COMPANY*w exp 99/99/999 | $872,000 | -21.0% | 100,000 | 0.0% | 0.10% | +7.9% | ||
| NRIX | Exit | NURIX THERAPEUTICS INC | $0 | – | -1,132,397 | -100.0% | -1.34% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -196,995 | -100.0% | -4.23% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCLS II Investco (GP), LLC #6
- BCLS II Investco, LP #7
- Bain Capital Life Sciences III General Partner, LLC #8
- Bain Capital Life Sciences Fund III, L.P. #9
- Bain Capital Life Sciences Opportunities III GP, LLC #10
- Bain Capital Life Sciences Opportunities III, LP #11
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SAVARA INC | 19 | Q2 2024 | 6.4% |
| X4 PHARMACEUTICALS INC | 19 | Q2 2024 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 18 | Q2 2024 | 20.1% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| MERSANA THERAPEUTICS, INC. | 17 | Q2 2024 | 8.4% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| ANNEXON INC | 16 | Q2 2024 | 9.1% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-12 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.